Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
1.050
+0.055 (5.51%)
At close: Aug 11, 2026, 4:00 PM EDT
1.020
-0.030 (-2.86%)
Pre-market: Aug 12, 2026, 5:16 AM EDT
Dyadic International Revenue
Dyadic International had revenue of $1.11M in the quarter ending March 31, 2026, with 182.28% growth. This brings the company's revenue in the last twelve months to $3.81M, up 7.13% year-over-year. In the year 2025, Dyadic International had annual revenue of $3.09M, down -11.59%.
Revenue (ttm)
$3.81M
Revenue Growth
+7.13%
P/S Ratio
10.05
Revenue / Employee
$761,546
Employees
5
Market Cap
38.26M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.09M | -405.04K | -11.59% |
| Dec 31, 2024 | 3.50M | 596.58K | 20.58% |
| Dec 31, 2023 | 2.90M | -31.50K | -1.07% |
| Dec 31, 2022 | 2.93M | 526.47K | 21.90% |
| Dec 31, 2021 | 2.40M | 801.91K | 50.06% |
| Dec 31, 2020 | 1.60M | -79.16K | -4.71% |
| Dec 31, 2019 | 1.68M | 385.63K | 29.77% |
| Dec 31, 2018 | 1.30M | 537.03K | 70.81% |
| Dec 31, 2017 | 758.42K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 31.52M |
| Veru Inc. | 16.89M |
| Radiopharm Theranostics | 10.86M |
| Apollomics | 8.84M |
| BeyondSpring | 1.88M |
| Nutriband | 1.80M |
| Hyperion DeFi | 1.04M |
| CervoMed | 331.30K |
DYAI News
- 7 days ago - Dyadic enters commercial license agreement with European biotechnology company - TheFly
- 7 days ago - Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement - GlobeNewsWire
- 8 days ago - Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026 - GlobeNewsWire
- 14 days ago - Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days - GlobeNewsWire
- 18 days ago - Dyadic International regains compliance with Nasdaq - TheFly
- 18 days ago - Dyadic Announces Continued Listing on the Nasdaq Capital Market - GlobeNewsWire
- 26 days ago - Dyadic expands bio-industrial pipeline with new industrial enzyme program - TheFly
- 26 days ago - Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program - GlobeNewsWire